BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38724832)

  • 1. Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy.
    Fu H; Wu S; Shen H; Luo K; Huang Z; Lu N; Li Y; Lan Q; Xian Y
    J Mol Neurosci; 2024 May; 74(2):52. PubMed ID: 38724832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
    Yang WH; Qiu Y; Stamatatos O; Janowitz T; Lukey MJ
    Trends Cancer; 2021 Aug; 7(8):790-804. PubMed ID: 34020912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
    Restall IJ; Cseh O; Richards LM; Pugh TJ; Luchman HA; Weiss S
    Cancer Res; 2020 Dec; 80(24):5478-5490. PubMed ID: 33106333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
    Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells.
    Wang D; Meng G; Zheng M; Zhang Y; Chen A; Wu J; Wei J
    PLoS One; 2016; 11(11):e0166423. PubMed ID: 27835669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.
    Jin H; Wang S; Zaal EA; Wang C; Wu H; Bosma A; Jochems F; Isima N; Jin G; Lieftink C; Beijersbergen R; Berkers CR; Qin W; Bernards R
    Elife; 2020 Oct; 9():. PubMed ID: 33016874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
    Chen Z; Li D; Xu N; Fang J; Yu Y; Hou W; Ruan H; Zhu P; Ma R; Lu S; Cao D; Wu R; Ni M; Zhang W; Su W; Ruan BH
    J Med Chem; 2019 Jan; 62(2):589-603. PubMed ID: 30543285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
    Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
    Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 15. Dihydroartemisin inhibits glioma invasiveness via a ROS to P53 to β-catenin signaling.
    Que Z; Wang P; Hu Y; Xue Y; Liu X; Qu C; Ma J; Liu Y
    Pharmacol Res; 2017 May; 119():72-88. PubMed ID: 28111262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
    Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
    Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
    Su Z; Han S; Jin Q; Zhou N; Lu J; Shangguan F; Yu S; Liu Y; Wang L; Lu J; Li Q; Cai L; Wang C; Tian X; Chen L; Zheng W; Lu B
    Cell Death Dis; 2021 Mar; 12(3):251. PubMed ID: 33674562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.